Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i). Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada. Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases. Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease. Implementation of Canada's action plan for pain and federal initiatives related to pain management. Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework. Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.